Literature DB >> 2670510

Management of chronic obstructive pulmonary disease.

S Kesten1, A S Rebuck.   

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by insidiously progressive airflow limitation. The necessarily multifactorial management programme should include smoking cessation, prevention of infections, bronchodilator and steroid therapy, supplemental oxygen, physical therapy, pulmonary rehabilitation programmes, psychosocial support and treatment of concomitant disease. There have been many advances in medical therapy but some of the notorious controversies remain. New sympathomimetic agents and methylxanthines, as well as the availability of inhaled anticholinergic medications free of toxicity, have led to improvement in symptoms and complications related to COPD. There is a clear place for the judicious use of systemic steroids.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2670510     DOI: 10.2165/00003495-198938010-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  69 in total

1.  Pneumococcal vaccine: the evidence mounts.

Authors:  F M LaForce; T C Eickhoff
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

2.  Influenza vaccine and pneumonia mortality in a nursing home population.

Authors:  A J Saah; R Neufeld; M Rodstein; J R La Montagne; W C Blackwelder; P Gross; G Quinnan; R A Kaslow
Journal:  Arch Intern Med       Date:  1986-12

3.  Influenza prevention, 1987-1988.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1987-08-28       Impact factor: 1.909

4.  Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients.

Authors:  B Burrows; R H Earle
Journal:  N Engl J Med       Date:  1969-02-20       Impact factor: 91.245

5.  Inspiratory muscle training compared with physiotherapy in patients with chronic airflow limitation.

Authors:  R L Pardy; R N Rivington; P J Despas; P T Macklem
Journal:  Am Rev Respir Dis       Date:  1981-04

6.  Effect of aminophylline on ventilatory responses in normal man.

Authors:  S Lakshminarayan; S A Sahn; J V Weil
Journal:  Am Rev Respir Dis       Date:  1978-01

7.  Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics.

Authors:  S Larsson; N Svedmyr
Journal:  Am Rev Respir Dis       Date:  1977-11

8.  Pneumococcal vaccine. Health and Public Policy Committee, American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

9.  A comparison of the effects of almitrine or oxygen breathing on pulmonary arterial pressure and right ventricular ejection fraction in hypoxic chronic bronchitis and emphysema.

Authors:  W MacNee; J J Connaughton; G B Rhind; M D Hayhurst; N J Douglas; A L Muir; D C Flenley
Journal:  Am Rev Respir Dis       Date:  1986-09

10.  Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency.

Authors:  R K Albert; T R Martin; S W Lewis
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

View more
  3 in total

Review 1.  Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors:  D Faulds; L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 2.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 3.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.